glp-1 drugs safe from the Gray Market GLP-1 receptor agonists | How

Results from a study examining the safety of using liraglutide in patients with moderate to severe renal impairment demonstrated no deleterious effects on serum creatinine (SCr) or increased incidence or severity of adverse events

doi: 10.1080/01616412.2016.1145914 198 PanagakiTMichaelMHolscherC

Clinical trials and regulatory bodies, including the MHRA (Medicines and Healthcare Products Regulatory Agency) and the EMA (European Medicines Agency), have approved it for managing diabetes and weight loss[1]

Rapid economic development, rising healthcare expenditure, growing diabetes epidemic and increasing focus of international players on emerging Asian markets can drive the market growth

it does not apply to grandfathered plans or large group plans

Mounjaro is made by Eli Lilly and contains the same active ingredient (tirzepatide) as Zepbound